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MAPK pathwaysd differentiation of growth plate chondrocytes is required for endochondral bone
growth, but the mechanisms and pathways that control these processes are not completely understood.
Recent data demonstrate important roles for nitric oxide (NO) and C-type natriuretic peptide (CNP) in the
regulation of cartilage development. Both NO and CNP stimulate the synthesis of cGMP and thus the
activation of common downstream pathways. One of these downstream mediators, cGMP-dependent kinase
II (cGKII), has itself been shown to be essential for normal endochondral bone formation. This review
summarizes our knowledge of the roles and mechanisms of NO, CNP and cGKII signaling in cartilage and
endochondral bone development.
© 2008 Elsevier Inc. All rights reserved.Endochondral ossiﬁcation
Skeletal development occurs through two different pathways:
endochondral and intramembranous ossiﬁcation. Intramembranous
bone forms by direct differentiation of mesenchymal cells into osteo-
blasts (cranial vault bones). However, the process of endochondral
ossiﬁcation is responsible for the development of the majority of our
bones. During this process, cartilage precursors are ﬁrst generated and
later replaced by bone (long bones, vertebral column, cranial base)
(Karsenty and Wagner, 2002; Olsen et al., 2000; Provot and Schipani,
2005; Wagner and Karsenty, 2001). During this process, cartilage cells
(chondrocytes) undergo a series of well-orchestrated phenotypic
changes required for the development and growth of bone. Initially,
mesenchymal precursor cells condense at the sites of future bone
formation. Increased cell density and cell–cell interactions result in
differentiation of these cells into chondrocytes, characterized by the
expression of speciﬁc transcription factors (e.g. Sox9) and extracellular
matrix (ECM)molecules such as collagen II and aggrecan (DeLise et al.,
2000) (Fig. 1). Cells in the center of these cartilage anlagen then
differentiate further into large (hypertrophic) postmitotic chondro-
cytes. Cartilage cells on either side of the hypertrophic center start
proliferating in an unidirectional manner along the longitudinal axise of Dentistry, Department of
treet, Rm 1028, New York, NY
ira).
l rights reserved.of the bone model, giving rise to the characteristic structure of the
growth plate (Kronenberg, 2003) (Fig. 1). In the growth plates, located
at the end of the long bones, chondrocytes undergo a series of tran-
sitions that form distinct zones. In the resting zone, immature chon-
drocytes accelerate their rate of cell cycle progression and give rise to
proliferative chondrocytes (Beier, 2005). After a number of divisions,
these cells withdraw from the cell cycle and start terminal diffe-
rentiation into hypertrophic chondrocytes. Finally, the hypertrophic
zone of the growth plate becomes mineralized, is invaded by blood
vessels, gradually resorbed and replaced by bone tissue.
Chondrocyte proliferation and hypertrophy, and ECM production,
are the driving forces of longitudinal growth of endochondral bones.
These processes are regulated by a plethora of hormones, growth
factors and other signals, through both local and systemic mechan-
isms. The endocrine factors that control bone growth include growth
hormone, glucocorticoids and thyroid hormones, while local factors
include parathyroid hormone-related peptide and members of the
transforming growth factor β, ﬁbroblast growth factor, hedgehog and
Wnt families, amongst others (Beier et al., 1999a; van der Eerden,
2003). The intracellular pathways that are triggered by many of these
signals in chondrocytes are not well understood. The best charac-
terized effectors include Sox9 and Runx2, two central transcription
factors that regulate early chondrocyte differentiation and hyper-
trophic differentiation, respectively (Kronenberg, 2003, 2006;
Lefebvre and Smits, 2005). In recent years, nitric oxide and C-type
natriuretic peptide have been identiﬁed as new regulators of endo-
chondral bone growth that act through a common mediator, cGMP.
Fig. 1. Scheme of endochondral bone formation during development. Initially the mesenchyme in the region of the future bone anlagen differentiates into chondrocytes, forming a
cartilagemodel of the future bone (A). Cells in the center of the cartilage model undergo further differentiation into hypertrophic cells inducing vascular invasion of the diaphysis and
formation of a marrow cavity. As a result of osteoclast and osteoblast activity, the cartilage is resorbed and the ﬁrst osteoid is deposited (B). Areas of secondary ossiﬁcation develop in
the epiphysis, while in the growth plate (gp), located between the epiphysis and diaphysis, columns of chondrocytes continue to proliferate, hypertrophy, secrete and mineralize the
extracellular matrix (C). Over time this matrix is partially resorbed and replaced with new bone resulting in bone elongation.
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way in endochondral ossiﬁcation is discussed in this review, and the
pathways are outlined in Fig. 2.
Nitric oxide in cartilage development
Nitric oxide (NO) was identiﬁed as the endothelial-derived
relaxation factor (Ignarro et al., 1987; Palmer et al., 1987), and the
importance of that pioneering work was recognized with the 1998
Nobel Prize in Physiology/Medicine. NO is an uncharged molecule
with an unpaired electron, which makes it an ideal messenger mole-
cule. Uncharged, NO can diffuse freely across membranes without
need for a receptor and the unpaired electron makes it a highly
reactive molecule (Lowenstein et al., 1994; Stamler et al., 1992). NO is
synthesized enzymatically from L-arginine in the presence of oxygen
by at least three different nitric oxide synthases. The neuronal (nNOS
or NOS1) and the endothelial (eNOS or NOS3) isoforms are cons-
titutively expressed, and their activity is regulated by intracellular
calcium levels and the calcium binding protein calmodulin. The indu-
cible isoform (iNOS or NOS2) is stimulated by factors that include
lipopolysacharide and cytokines such as IL-1, TNFα and IFNα, and its
activation leads to a sustained generation of NO (Stadler et al., 1991).
A well studied model of NO action involves its binding to the
heme-containing soluble protein guanylate cyclase, causing increasedenzymatic activity and formation of cGMP. Depending on the cell type,
the increase in cGMP concentration may lead to activation of phos-
phodiesterases, cGMP-regulated ion channels and cGMP-dependent
kinases (cGKs) (Fig. 2) (Knowles and Moncada, 1998). NO may also
change the enzymatic function of other heme-containing proteins,
cyclooxygenase 1 and 2, and in this way modulate inﬂammatory
responses (Stamler, 1994; Stamler et al., 1992). NO can inﬂuence the
activity of a number of biochemical pathways by reacting with thiol-
containing domains in a number of proteins, Enzymes that contain
cysteines in their active sites, such as glyceraldehyde-3-phosphate,
alcohol and aldehyde dehydrogenases, aremost amenable to this form
of control (Stamler, 1994), implicating NO in the regulation of cellular
metabolism. Aside from its role in modulating energy status, NO can
also serve to control cell proliferation (in Drosophila imaginal discs)
and cell death in different systems (chondrocytes, hepatocytes,
macrophages, neurons, and others) (Blanco and Lotz, 1995; Blanco et
al., 1995; Kim et al., 2005; Kuzin et al., 1996; Marriott et al., 2004;
Peunova and Enikolopov, 1998).
Research on the role of NO in the regulation of chondrocyte func-
tion has focused on the articular chondrocyte and the osteoarthritic
joint cartilage. NO plays a role in almost every aspect of osteoarthritis
pathophysiology. The effects of NO on articular chondrocytes include
inhibition of cartilage matrix synthesis, acceleration of chondrocyte-
mediated matrix degradation, promotion of chondrocyte inﬂamma-
Fig. 2. Scheme of cGMP pathways active in growth plate cartilage. Nitric oxide (NO) generation by nitric oxide synthases (NOS) present in chondrocytes leads to activation of the
soluble guanylate cyclase (sGC) and an increase in the intracellular levels of cGMP. Binding of the C-type natriuretic peptide (CNP) to the natriuretic peptide receptor B (NPR2) also
increases cGMP levels in chondrocytes. The increase in cGMP concentration may lead to activation of phosphodiesterases (PDE), cGMP-regulated ion channels (ICH) and cGMP-
dependent kinases (cGK). In particular, cGK II has been shown to play an important role in endochondral bone formation. Possible downstream pathways include the inhibition of
nuclear translocation of the transcription factor Sox 9 (SOX9), and the repression of FGF signaling and ERK activation through Raf 1.
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Amin and Abramson, 1998; Lotz, 1999). Interestingly, our recent stu-
dies have shown that the three NOS isoforms are also expressed by
growth plate chondrocytes, and NO adducts (nitroso cysteine, nitro-
tyrosine) accumulate in the hypertrophic and calciﬁed regions of the
chick cartilage (Teixeira et al., 2005). In culture, growth plate chon-
drocytes can generate levels of NOmetabolites comparable to articular
chondrocytes (Hauselmann et al., 1998; Palmer et al., 1993; Taskiran et
al., 1994) as well as other cells (Chang et al., 1996; MacPherson et al.,
1999). Furthermore, both cGMP-dependent and -independent path-
ways mediate the effect of NO in growth plate chondrocytes. Using an
in vitro model for chondrocyte maturation we have found that NO
donors (S-nitrosoglutathione, S-Nitroso-N-acetyl-DL-penicillamine,
spermine–nitric oxide) or transfection with eNOS enhanced the
expression of markers of hypertrophy, such as type X collagen and
alkaline phosphatase activity. Conversely, inhibition of NOS (NG-nitro-
L-arginnine methyl ester, NG-Monomethyl-L-arginnine), guanylate
cyclase (1H-[1,2,4] Oxadiazolo[4,3-a]quinoxalin-1-one) or cGKs (KT
5823) blocked retinoic acid-induced chondrocytematuration (Teixeira
et al., 2003). Once chondrocytes became hypertrophic, the same NO
donors were capable of inducing chondrocyte apoptosis in a cGMP-
independentmanner. In cultured hypertrophic chondrocytes, blocking
NO generation with NOS inhibitors prevented loss of reduced thiols,
mitochondria depolarization, and ultimately phosphate-induced
apoptosis (Teixeira et al., 2001). These in vitro data suggest that
distinct NO pathways may be active at different stages of chondrocyte
differentiation and maturation during endochondral bone formation.
However, the in vivo role of NO and the different NOS genes in
endochondral ossiﬁcation still awaits detailed analyses. The eNOS
knockoutmice present limb deﬁciencies, with terminal and transversedefects of both hind limbs and forelimbs (Heﬂer et al., 2001). The
weight and crown-rump length were signiﬁcantly reduced (10%) in
the knockout animals, with continued growth delays from E17 to
21 days postnatal. Other abnormalities ranged from meromelia to
syndactyly, and hypoplasia of carpals, metacarpals, radius and ulna
(Table 1). It was proposed that these abnormalities were caused by
insufﬁcient blood ﬂow to the limbs and hemorrhage. Microscopic
ﬁndings were consistent with vascular etiology, with constricted arte-
rioles, hemorrhage and necrosis observed in the area of the cartilage
anlagen. While no growth abnormalities have been described for the
iNOS and nNOS knockout animals, suggesting compensatory interac-
tions among the different isoforms, the administration of NOS inhi-
bitors to the drinking water of pregnant rats induced fetal growth
retardation and hind limb disruptions in the pups (Diket et al., 1994).
These alterations were also attributed to disturbed blood ﬂow to the
developing limbs, but direct effects on skeletal elements cannot be
excluded and await further investigation.
Interestingly, the double knockouts for two NOS isoforms
(including eNOS) do not present signiﬁcant growth defects, suggest-
ing that the presence of a single NOS isoform allows compensatory
NO production (Tranguch and Huet-Hudson, 2003). However,
increased embryonic lethality in double knockouts suggests the
occurrence of major developmental abnormalities (that were not
investigated further) and underlines the importance of these path-
ways during development. Mice lacking all three NOS isoforms also
have a low number of offspring as well as a very low survival rate
(Morishita et al., 2005; Tsutsui et al., 2006). Postnatal death occurred
mostly due to cardiovascular disease. Surprisingly, no gross growth
defects were described for the surviving triple knockout suggesting
that the phenotype is variable, ranging from very mild phenotypes to
Table 1
Mutants in the natriuretic peptide and nitric oxide pathways with skeletal phenotypes
Common name Gene name Mutation Skeletal phenotype Reference
CNP Nppc (human) Translocation, overexpression Tall, stature, bone abnormalities Bocciardi et al. (2007)
Nppc (mouse) KO Dwarﬁsm, smaller, proliferative and hypertrophic
zones in growth plate
Chusho et al. (2001)
Cartilage overexpression Rescues effects of Nppc KO rescues model of
achondrodysplasia
Chusho et al. (2001)
BNP Nppb (mouse) Ubiquitous overexpression Skeletal overgrowth Suda et al. (1998)
NPR2 NPR2 (human) Loss-of-function Acromesomelic dysplasia, type Maroteaux short stature Bartels et al. (2004)
Npr2 (mouse) Natural loss-of-function Cn mice, dwarﬁsm, short limbs Tamura et al. (2004)
KO Dwarﬁsm, reduced endochondral bone growth Tsuji and Kunieda (2005)
NRP3 Npr3 (mouse) Natural loss-of-function Skeletal overgrowth Jaubert et al. (1999)
KO Overgrowth of long bones increased skeletal turnover Matsukawa et al. (1999)
cGK II Prkg2 (mouse) KO Dwarﬁsm, disorganized growth plate Pfeifer et al. (1996)
Prkg2 (rat) Natural loss-of-function Komeda miniature rat Ishikawa dwarﬁsm, abnormal
growth plates
Chikuda et al. (2004)
eNOS NOS3 (Mouse) KO Limb abnormalities (low penetrance) short digits Gregg et al. (1998);
Heﬂer et al. (2001)
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completed, neither during embryonic development nor postnatally.
Therefore, while our in vitro studies clearly show a role for NO in
growth plate cartilage, no deﬁnite conclusion can be drawn from
current in vivo observations.
NO is also an important signaling molecule in bone in response to
different stimuli including inﬂammatory cytokines and mechanical
stress (Klein-Nulend et al., 1998; MacPherson et al., 1999; van't Hof
and Ralston, 2001). Major defects in osteoblast activity (reduced
proliferation, differentiation and mineralization) have been reported
both in vivo and in vitro, in eNOS knockout animals (Aguirre et al.,
2001; Armour et al., 2001), and NO produced by eNOS mediates the
effect of sex hormones in bone (Grassi et al., 2006; Wimalawansa et
al., 1996). Furthermore, NOS inhibitors or high concentrations of NO
reduce the formation, activity andmotility of osteoclasts (Brandi et al.,
1995). The nNOS knockout mice have reduced osteoclast numbers and
activity both in vivo and in vitro (Jung et al., 2003). However, the study
of the eNOS and iNOS deﬁcient mice showed no major defect in bone
resorption, suggesting some NO effects on osteoclasts are indirect,
either mediated by osteoblasts and/or inﬂammatory pathways (van't
Hof and Ralston, 2001). While these NO effects on bone function could
help explain some of the growth abnormalities in the knockout
animals, our previous work suggests that the process of endochondral
bone formation is affected by the altered activity of growth plate
chondrocytes themselves. Due to indirect effects of NO in different cell
types involved in endochondral ossiﬁcation (osteoblast, chondrocytes,
osteoclasts, endothelial cells), clariﬁcation of the role of NO in this
process will require generation and analyses of tissue speciﬁc knock-
out mice.
C-type natriuretic peptide in endochondral ossiﬁcation
The second main class of cGMP inducers are the natriuretic pep-
tides, ANP (atrial natriuretic peptide), BNP (brain natriuretic peptide)
and CNP (C-type natriuretic peptide). These are secreted peptides
that control cell behavior through activation of two transmembrane
receptors, NPR1 and NPR2 (natriuretic peptide receptor 1 and 2)
(Anand-Srivastava, 2005; Baxter, 2004; Cea, 2005; Leist et al., 1997;
Potter et al., 2006). Importantly, these receptors possess guanylyl
cyclase activity, synthesize cGMP in response to ligand binding and
are thus also known as GC-A and GC-B (guanylyl cyclase A and B). ANP
and BNP signal mainly through NPR1/GC-A, while CNP predominantly
activates NPR2/GC-B. All three ligands also bind to a third receptor,
NPR3, that is thought to act mainly as a clearance receptor that limits
ligand availability and natriuretic peptide signaling.
While several in vitro studies had suggested a role of natriuretic
peptide signaling in chondrocytes (Fujishige et al., 1999; Hagiwara etal., 1996,1994; Mericq et al., 2000; Yasoda et al., 1998), the importance
of this pathway for endochondral ossiﬁcation was only fully recog-
nized after disruption of the CNP gene in mice (Chusho et al., 2001).
The most striking phenotype of these mice is severe dwarﬁsm caused
by direct effects on growth plate chondrocytes. At birth, these mice
display a 10% reduction in length, but the growth retardation becomes
more severe postnatally, and about 70% of null mice die in the ﬁrst
100 days after birth. Notably, all endochondral bones examined (e.g.
long bones, vertebrae) show growth reduction, whereas intramem-
braneous bones were of normal size. Furthermore, cartilage-speciﬁc
overexpression of CNP rescued the phenotype of CNP-deﬁcient mice,
strongly suggesting that CNP stimulates bone growth through direct
effects on chondrocytes (rather than systemically). In agreement with
this phenotype, organ culture studies of endochondral bones showed
that exogenous CNP is a potent stimulator of longitudinal bone growth
(Mericq et al., 2000; Yasoda et al., 1998).
Subsequent to the description of CNP-deﬁcient mice, it was shown
that targeted inactivation as well as naturally occurring mutations of
the Npr2 gene (encoding the CNP receptor) result in a similar pheno-
type (Tsuji and Kunieda, 2005; Yasoda et al., 2004). In particular, Npr2-
null mice display signiﬁcantly reduced postnatal growth of endo-
chondral, but not intramembranous, bones and increased mortality
(Yasoda et al., 2004). In contrast, both natural and engineered loss-of-
function mutants of the Npr3 gene show the opposite phenotype of
skeletal overgrowth (Jaubert et al., 1999; Matsukawa et al., 1999).
These ﬁndings support a model where CNP promotes endochondral
bone growth through NPR2, whereas the decoy receptor NPR3 anta-
gonizes this activity. In contrast, mice deﬁcient for ANP, BNP or NPR1
genes do not display skeletal phenotypes (Enomoto et al., 2000;
Jimenez et al., 1999; John et al., 1995, 1996), suggesting that these
genes play minor role, if any, in endochondral ossiﬁcation. Over-
expression of BNP in transgenicmice has been shown to cause skeletal
overgrowth, but this is most likely due to stimulation of NPR2 by
unphysiologically high levels of BNP (Suda et al., 1998).
The cellular mechanisms of CNP action on chondrocytes are
complex. The proliferative zone of the growth plate is shortened in
mice deﬁcient for CNP or NPR2, but while CNP-null mice show lower
proliferation rates (Chusho et al., 2001), these rates appear to be
unchanged in the absence of NPR2 (Yasoda et al., 2004). One possible
explanation for these contradictory results is that CNP might not
affect the rate of cell cycle progression while cells proliferate (e.g. no
differences in the proportion of cells in the S-phase within the
proliferative zone), but possibly controls the timing of cell cycle exit,
thus affecting the length of the proliferating zone and the proportion
of S phase cells within the context of the entire growth plate. While
the effects of CNP on chondrocyte proliferation are still not
completely clear, the more dramatic phenotype in both CNP- and
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Similarly, CNP treatment of endochondral bones in organ cultures
resulted in longer hypertrophic zones (Agoston et al., 2007; Mericq et
al., 2000), due to increased number and size of hypertrophic
chondrocytes. No differences in chondrocyte apoptosis were
observed in CNP-deﬁcient mice (Chusho et al., 2001). Finally, CNP
has been shown to increase the production of extracellular matrix
(ECM) and the expression of genes involved in proteoglycan synthesis
(Krejci et al., 2005; Mericq et al., 2000; Woods et al., 2007) and to
suppress the expression of enzymes involved in ECM breakdown
(Krejci et al., 2005). Together, these data suggest a model where CNP
promotes endochondral bone growth through several mechanisms,
including the stimulation of chondrocyte proliferation, the promotion
of chondrocyte hypertrophy and the enhancement of extracellular
matrix synthesis by chondrocytes.
Another landmark discovery was the identiﬁcation of mutations in
the human NPR2 gene as the cause of acromesomelic dysplasia, type
Maroteaux, a rare human chondrodysplasia characterized by dwarf-
ism (Bartels et al., 2004). Heterozygosity for this mutation is
associated with short stature (Olney et al., 2006). The fact that loss
of one functional allele of NPR2 is sufﬁcient to affect height conﬁrms
the clinical importance of the CNP signaling system in controlling
endochondral bone growth. Very recently, skeletal overgrowth in one
patient was correlated with increased CNP expression due to a chro-
mosomal translocation involving the NCCP gene that encodes CNP
(Bocciardi et al., 2007).
The importance of the CNP signaling system in mammalian
endochondral ossiﬁcation is now clearly established, and focus has
recently shifted towards the analyses of both the upstream regulators
and the downstream mechanisms of CNP signaling in skeletal
development. CNP is thought to act in an auto-/paracrine manner,
but is expressed in and acts on multiple tissues, some of which have
the potential to indirectly control bone growth. For example, CNP
controls pituitary growth hormone secretion (McArdle et al., 1994;
Shimekake et al., 1994) which is known to regulate endochondral
bone growth. However, chondrocytes express both CNP and NPR2
(Chusho et al., 2001), suggesting that local effects constitute the
majority of the anabolic effects of this pathway. This model is further
supported by the observation that CNP overexpression in cartilage
rescues the effects of the CNP knockout (Chusho et al., 2001) and that
CNP application in organ cultures mimics these effects. However, the
question arises how CNP signaling is coordinated with the many
other signaling systems controlling endochondral ossiﬁcation.
Whether the CNP axis is regulated by systemic/endocrine factors is
of particular interest. Our recent in vitro studies have shown that the
glucocorticoid Dexamethasone increases CNP mRNA expression in
chondrocytes (Agoston et al., 2006) should however, since gluco-
corticoids (at least in the applied pharmacological doses) suppress
bone growth (Baron et al., 1992; Robson et al., 2002; Siebler et al.,
2001), the physiological signiﬁcance of these data needs to be
established.
Using microarray analyses of microdissected mouse tibiae, we
determined that CNP, NPR2 and NPR3 are expressed in all zones of the
growth plate (Agoston et al., 2007). Interestingly, transcript levels for
both cGKI and II are strongly upregulated during chondrocyte diffe-
rentiation, in agreement with earlier immunohistochemistry data
(Pfeifer et al., 1996). However, these data also identiﬁed a feedback
loop where endogenous CNP induces the expression of its decoy
receptor NPR3. A different feedback loop has recently been described
in smooth muscle cells where CNP suppresses expression of NPR2
(Rahmutula and Gardner, 2005). Thus, it appears that the CNP sig-
naling system exerts a high level of self-control to ﬁne tune its activity.
However, very little is known about regulation of CNP signaling com-
ponents by other local or systemic factors involved in skeletal growth
control, with exception of the crosstalk with ﬁbroblast growth factor
signaling described below.CNP effectors
In contrast to the upstream regulators, more insight has been
obtained into the downstream mechanisms of CNP signaling in
cartilage. CNP induces synthesis of cGMP and thus activation of several
downstream pathways (Fig. 2), namely cGMP-dependent kinases,
phosphodiesterases and speciﬁc ion channels. Since NO also induces
cGMP synthesis, it is likely that it shares many of the biological
activities of CNP described below; however, this has not been formally
demonstrated (to our knowledge).
To date, analyses of cGMP effectors in cartilage have been largely
restricted to cGKs. The description of growth plate deﬁciencies in
cGKII null mice (Pfeifer et al., 1996) predated the recognition of CNP's
importance in cartilage. The cartilage phenotype of cGKII null mice
shows both similarities with and differences from that of CNP null
mice. CNP-deﬁcient mice display greater and earlier growth reduction
and increased postnatal lethality than cGKII null mice, although
disorganization of the growth plate appears to bemore severe in cGKII
mutant mice (Pfeifer et al., 1996). Notably, cGKII deﬁciency blocks the
anabolic effects of CNP overexpression in the cartilage of transgenic
mice, demonstrating that cGKII is required for CNP effects on bone
growth (Miyazawa et al., 2002). However, these data do not exclude a)
additional (although potentially minor) roles of cGKI or other effectors
of cGMP in CNP signaling, and b) contributions from additional
upstream activators of cGKII (such as nitric oxide) in cartilage. A loss-
of-function mutation in the cGKII gene has also recently been
identiﬁed as the cause of dwarﬁsm in the naturally occurring Komeda
miniature rat Ishikawa (KMI) strain (Chikuda et al., 2004).
Identiﬁcation of downstream mediators of cGKs is currently under
way in several laboratories. It was noticed early on that CNP-deﬁcient
mice displayed features of achondroplasia, the most common form of
human dwarﬁsm. Achondroplasia is caused by activating mutations in
the ﬁbroblast growth factor receptor 3 (FGFR3) gene (Bellus et al.,
1995; Bonaventure et al., 1996; Rousseau et al., 1994; Shiang et al.,
1994), resulting in constitutive activation of the receptor and down-
stream pathways, including STAT1 and ERK1/2 signaling (Ornitz,
2005). Yasoda and colleagues (Yasoda et al., 2004) demonstrated that
overexpression of CNP in cartilage rescues dwarﬁsm and other
phenotypes in a mouse model of achondroplasia. Not only does this
study suggest a potential for CNP in the treatment of some forms of
human dwarﬁsm, it also demonstrates that the FGF and CNP signaling
pathways are intimately linked in the control of endochondral bone
growth. Yasoda et al. showed that CNP signaling blocks activation
of the ERK (but not the STAT1) pathway by FGF signaling. These
ﬁndings were further substantiated and extended by subsequent
studies demonstrating that CNP repression of ERK activation requires
cGK activity and occurs at the level of the MAP kinase kinase kinase
Raf1 (Krejci et al., 2005), a major mediator of FGFR3 signaling that has
been implicated in control of chondrocyte differentiation (Beier et al.,
1999b,c). In addition, it was shown that interaction between the two
pathways is reciprocal in that FGF signaling blocks CNP-induced cGMP
production in a MAPK-dependent manner (Yasoda et al., 2004).
p38 kinases constitute a second MAPK pathway that controls
chondrocyte differentiation in vitro and in vivo (Agoston et al., 2007;
Zhang et al., 2006, 2001). Our recent data show that CNP activates the
p38 pathway in primary chondrocytes and in tibia organ cultures
(Agoston et al., 2007). Moreover, pharmacological inhibition of p38
blocks the anabolic effects of CNP in mouse tibia organ cultures.
However, not all effects of CNP in organ cultures required p38 activity;
for example, CNP induction of several downstream genes was not
affected by p38 inhibitors. In addition to these two MAP kinase
pathways, our results also suggest roles for the PI3 K/Akt pathway in
CNP-induced bone growth (Ulici et al., 2008), suggesting a complex
network of signaling interactions in response to CNP.
Another mechanism of action for cGK signaling in cartilage was
elucidated in studies of the KMI rat (Chikuda et al., 2004). The authors
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drogenic transcription factor Sox9 into the cell nucleus. Downre-
gulation of Sox9 activity is required for hypertrophic differentiation,
but loss of cGKII leads to prolonged activity of Sox9, resulting in loss of
coordination between chondrocyte proliferation and differentiation
and thus in dwarﬁsm. While cGKII was shown to induce Sox9 phos-
phorylation in this study, it is not clear whether this occurs through
direct interaction or involves intermediary kinases. In addition, phos-
phorylation does not appear to be required for inactivation of Sox9 by
cGKII.
Open questions
Over the last few years, signiﬁcant progress has been made in our
understanding of NO, CNP and cGMP signaling during cartilage
development. Findings from human diseases, spontaneous mutations
in rodents and genetically engineered mice have demonstrated
unequivocally that the CNP-cGMP pathway is a central regulator of
endochondral ossiﬁcation. However, numerous questions and chal-
lenges remain and need to be solved in order to contemplate thera-
peutic applications. For example, the role of the nitric oxide pathway
in endochondral ossiﬁcation in vivo is still poorly understood and will
require detailed analyses of knockout mice for single and multiple
NOS genes. The contribution of cGMP effectors other than cGKs to the
activities of NO and CNP needs to be investigated. Interaction of the
different downstream effectors of cGMP/cGKs – such as the various
MAP kinases and other kinases – has not been addressed. Substrates of
these kinases in chondrocytes (e.g. transcription factors) and direct
target genes of the cGMP pathway need to be identiﬁed. While we
have recently performed microarray studies on CNP-treated tibiae
(Agoston et al., 2007), these were done at a late time point (six days of
stimulation) and not designed to identify direct target genes.
Interaction of the CNP pathway with other signals (in addition to
FGFs) in endochondral ossiﬁcation needs to be examined in detail. Are
components of the NO/CNP/cGMP pathways regulated by other sys-
temic or paracrine regulators of endochondral bone growth, such as
growth hormone, Indian hedgehog or parathyroid hormone-related
peptide? Conversely, do CNP and/or NO regulate these pathways? Our
microarray analyses indeed identiﬁed factors such as the BMP family
member GDF15 as target genes of CNP in chondrocytes (Agoston et al.,
2007), but detailed analyses of effects on spatial and temporal ex-
pression patterns of key regulators of cartilage development (e.g.
FGFR3, IHH etc.) still needs to be performed. Another question is
whether and where NO/CNP and other pathways intersect in the
intracellular signaling cascades or at speciﬁc target genes. Mouse
models with deﬁciencies in NO and CNP pathways show clear diffe-
rences as discussed above. In general, interruption of CNP signaling
appears to have more drastic consequences than disturbance of NO
signaling. Potential explanations for these discrepancies include
greater redundancy among NO-producing enzymes, differential cou-
pling to downstream mediators, additional roles in other cell types
(e.g. endothelial cells) and potential effects of genetic background.
In addition, it will be of great interest to further examine the roles
of NO and CNP in articular chondrocytes and osteoarthritis. While NO
is an established player in this context (Abramson et al., 2001; Finger
et al., 2003; Scher et al., 2007), CNP has, to our knowledge, never been
implicated in osteoarthritis. However, a recent study shows that CNP
can induce hypertrophy in articular chondrocytes (Johnson et al.,
2003), which is thought to contribute to disease progression. Thus,
while current evidence suggests that CNP/cGMP signaling might be of
use in the treatment of growth retardation, potential detrimental
effects on articular cartilage need to be considered.
Another unexplored area is the relationship between CNP and NO
signaling. While both pathways converge on a common mediator
(cGMP), it is not clear whether they act in an additive or synergistic
manner, or whether both have unique roles based on developmentalstage and/or location within the body. Compound mutants will be
very useful to address these questions (e.g. do double knockout mice
for CNP and a NOS gene have a more severe phenotype? Can over-
expression of a NOS gene in cartilage rescue the effects of CNP
deﬁciency?). Similarly, we don’t know whether these two pathways
directly regulate each other; for example, our data show upregulation
of Npr3 expression in response to CNP — can increased NO levels
perform the same function? Does CNP affect NO levels and/or NOS
expression and function?
While numerous questions remain to be answered, the combina-
tion of high throughput technologies in genomics and proteomics
with sophisticated in vivo models and real-time imaging of signaling
processes will solve many of these questions over the next years.
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